UTHR— UNITED THERAPEUTICS Corp

MaterialsBiotechnology$22.5B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$3.18B+10.6%	$2.88B+23.6%	$2.33B+20.2%	$1.94B
Cost of sales	$384.4M+24.1%	$309.7M+20.3%	$257.5M+69.9%	$151.6M
Research and development	$550.0M+14.3%	$481.0M+17.9%	$408.0M+26.4%	$322.9M
Selling, general, and administrative	$755.8M+6.5%	$709.7M+48.8%	$477.1M-1.0%	$482.1M
Total operating expenses	$1.69B+12.6%	$1.50B+31.3%	$1.14B+19.4%	$956.6M
Operating income	$1.49B+8.4%	$1.38B+16.2%	$1.18B+20.9%	$979.7M
Interest income	$192.0M-3.6%	$199.1M+22.4%	$162.7M+260.0%	$45.2M
Interest expense	-$19.5M+54.5%	-$42.9M+27.7%	-$59.3M-83.0%	-$32.4M
Other income (expense), net	$48.9M+743.1%	$5.8M+141.4%	-$14.0M+65.2%	-$40.2M
Total other income, net	$221.4M+36.7%	$162.0M+81.2%	$89.4M+407.2%	-$29.1M
Income before income taxes	$1.71B+11.4%	$1.54B+20.8%	$1.27B+34.1%	$950.6M
Income tax expense	-$379.2M-10.3%	-$343.9M-18.8%	-$289.5M-29.6%	-$223.3M
Net income	$1.33B+11.7%	$1.20B+21.4%	$984.8M+35.4%	$727.3M
Basic (in dollars per share)	$30130000.00+14.0%	$26440000.00+25.7%	$21040000.00+31.7%	$15980000.00
Diluted (in dollars per share)	$27860000.00+13.1%	$24640000.00+24.4%	$19810000.00+32.1%	$15000000.00
Basic (in shares)	44.3M-2.0%	45.2M-3.4%	46.8M+2.9%	45.5M
Diluted (in shares)	47.9M-1.2%	48.5M-2.4%	49.7M+2.5%	48.5M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.